American Journal of Epidemiology Advance Access originally published online on July 5, 2007
American Journal of Epidemiology 2007 166(7):817-823; doi:10.1093/aje/kwm147
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL CONTRIBUTIONS |
A Prospective Study of the Effectiveness of the New Zealand Meningococcal B Vaccine
1 School of Mathematics, Statistics, and Computer Science, Victoria University, Wellington, New Zealand
2 Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand
3 Current affiliation: Statistical & Data Sciences Practice, Exponent, San Diego, CA
Correspondence to Dr. Richard Arnold, School of Mathematics, Statistics, and Computer Science, Victoria University, P.O. Box 600, Wellington 6140, New Zealand (e-mail: Richard.Arnold{at}mcs.vuw.ac.nz).
Received for publication October 30, 2006. Accepted for publication April 11, 2007.
The effectiveness of a new group B strain-specific meningococcal vaccine referred to as "MeNZB," developed by Chiron Vaccines (Siena, Italy) in collaboration with the Norwegian Institute of Public Health, was assessed in a prospective observational study following a nationwide vaccination program in New Zealand. The vaccination program began in July 2004, and the study uses data from January 2001 to June 2006. A generalized estimating equation model was used to estimate vaccine effectiveness that included potential confounding variables, such as disease progression over time, age, ethnicity, socioeconomic status, seasonality, and geographic region. The model provides strong statistical evidence for a vaccine effect (p < 0.0001), with estimated disease rates 3.7 times higher in the unvaccinated group than in the vaccinated group (95% confidence interval: 2.1, 6.8) and a vaccine effectiveness of 73% (95% confidence interval: 52, 85). An estimated 54 epidemic strain meningococcal cases were prevented in the 2 years since the vaccination program began (95% confidence interval assuming a fixed population size: 22, 115). In a sensitivity analysis, these estimates proved to be robust to modeling assumptions, including population estimates, estimates of the numbers vaccinated, effects of partial vaccination, and temporal autocorrelation.
epidemiologic methods; evaluation studies; generalized estimating equation; immunization programs; meningococcal infections; Poisson regression; product surveillance, postmarketing; vaccines
Abbreviations: GEE, generalized estimating equation; NIR, National Immunization Register
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. T. Beernink, J. A. Welsch, M. Bar-Lev, O. Koeberling, M. Comanducci, and D. M. Granoff Fine Antigenic Specificity and Cooperative Bactericidal Activity of Monoclonal Antibodies Directed at the Meningococcal Vaccine Candidate Factor H-Binding Protein Infect. Immun., September 1, 2008; 76(9): 4232 - 4240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Beernink and D. M. Granoff Bactericidal Antibody Responses Induced by Meningococcal Recombinant Chimeric Factor H-Binding Protein Vaccines Infect. Immun., June 1, 2008; 76(6): 2568 - 2575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kelly, R. Arnold, Y. Galloway, and J. O'Hallahan THE AUTHORS REPLY Am. J. Epidemiol., May 1, 2008; 167(9): 1141 - 1142. [Full Text] [PDF]
|
|
|
|
|
|
D. Lennon, J. Stewart, and S. Crengle RE: "A PROSPECTIVE STUDY OF THE EFFECTIVENESS OF THE NEW ZEALAND MENINGOCOCCAL B VACCINE" Am. J. Epidemiol., May 1, 2008; 167(9): 1140 - 1141. [Full Text] [PDF]
|
|